320 related articles for article (PubMed ID: 28596971)
1. Soluble Urokinase Receptor and the Kidney Response in Diabetes Mellitus.
Dande RR; Peev V; Altintas MM; Reiser J
J Diabetes Res; 2017; 2017():3232848. PubMed ID: 28596971
[TBL] [Abstract][Full Text] [Related]
2. Urokinase plasminogen activator receptor and its soluble form in common biopsy-proven kidney diseases and in staging of diabetic nephropathy.
Wu CZ; Chang LC; Lin YF; Hung YJ; Pei D; Chu NF; Chen JS
Clin Biochem; 2015 Dec; 48(18):1324-9. PubMed ID: 26162494
[TBL] [Abstract][Full Text] [Related]
3. Inhibiting the urokinase-type plasminogen activator receptor system recovers STZ-induced diabetic nephropathy.
Dal Monte M; Cammalleri M; Pecci V; Carmosino M; Procino G; Pini A; De Rosa M; Pavone V; Svelto M; Bagnoli P
J Cell Mol Med; 2019 Feb; 23(2):1034-1049. PubMed ID: 30426662
[TBL] [Abstract][Full Text] [Related]
4. Glomerular podocytes in diabetic renal disease.
Podgórski P; Konieczny A; Lis Ł; Witkiewicz W; Hruby Z
Adv Clin Exp Med; 2019 Dec; 28(12):1711-1715. PubMed ID: 31851794
[TBL] [Abstract][Full Text] [Related]
5. Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunction.
Qi W; Keenan HA; Li Q; Ishikado A; Kannt A; Sadowski T; Yorek MA; Wu IH; Lockhart S; Coppey LJ; Pfenninger A; Liew CW; Qiang G; Burkart AM; Hastings S; Pober D; Cahill C; Niewczas MA; Israelsen WJ; Tinsley L; Stillman IE; Amenta PS; Feener EP; Vander Heiden MG; Stanton RC; King GL
Nat Med; 2017 Jun; 23(6):753-762. PubMed ID: 28436957
[TBL] [Abstract][Full Text] [Related]
6. Mangiferin prevents diabetic nephropathy progression and protects podocyte function via autophagy in diabetic rat glomeruli.
Wang X; Gao L; Lin H; Song J; Wang J; Yin Y; Zhao J; Xu X; Li Z; Li L
Eur J Pharmacol; 2018 Apr; 824():170-178. PubMed ID: 29444469
[TBL] [Abstract][Full Text] [Related]
7. Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes.
Theilade S; Lyngbaek S; Hansen TW; Eugen-Olsen J; Fenger M; Rossing P; Jeppesen JL
J Intern Med; 2015 Mar; 277(3):362-371. PubMed ID: 24830873
[TBL] [Abstract][Full Text] [Related]
8. Rethinking glomerular basement membrane thickening in diabetic nephropathy: adaptive or pathogenic?
Marshall CB
Am J Physiol Renal Physiol; 2016 Nov; 311(5):F831-F843. PubMed ID: 27582102
[TBL] [Abstract][Full Text] [Related]
9. Expression of Urokinase-type Plasminogen Activator Receptor and its Soluble Form in Type 2 Diabetic Kidney Disease.
Zhou Y; Ren J; Li P; Ma R; Zhou M; Zhang N; Kong X; Hu Z; Xiao X
Arch Med Res; 2019 Jul; 50(5):249-256. PubMed ID: 31593848
[TBL] [Abstract][Full Text] [Related]
10. Serum soluble urokinase plasminogen activator receptor as a potential biomarker of renal impairment severity in diabetic nephropathy.
Lupușoru G; Ailincăi I; Sorohan BM; Andronesi A; Achim C; Micu G; Caragheorgheopol A; Manda D; Lupușoru M; Ismail G
Diabetes Res Clin Pract; 2021 Dec; 182():109116. PubMed ID: 34728182
[TBL] [Abstract][Full Text] [Related]
11. Diabetic kidney lesions of GIPRdn transgenic mice: podocyte hypertrophy and thickening of the GBM precede glomerular hypertrophy and glomerulosclerosis.
Herbach N; Schairer I; Blutke A; Kautz S; Siebert A; Göke B; Wolf E; Wanke R
Am J Physiol Renal Physiol; 2009 Apr; 296(4):F819-29. PubMed ID: 19211686
[TBL] [Abstract][Full Text] [Related]
12. Podocyte Autophagy: A Potential Therapeutic Target to Prevent the Progression of Diabetic Nephropathy.
Liu N; Xu L; Shi Y; Zhuang S
J Diabetes Res; 2017; 2017():3560238. PubMed ID: 28512641
[TBL] [Abstract][Full Text] [Related]
13. SGLT2 Inhibitors and the Diabetic Kidney.
Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
[TBL] [Abstract][Full Text] [Related]
14. [Diabetes mellitus and chronic kideny disease: modern diagnostics and treatment].
Shestakova MV
Vestn Ross Akad Med Nauk; 2012; (1):45-9. PubMed ID: 22550710
[TBL] [Abstract][Full Text] [Related]
15. Enhanced glomerular Toll-like receptor 4 expression and signaling in patients with type 2 diabetic nephropathy and microalbuminuria.
Verzola D; Cappuccino L; D'Amato E; Villaggio B; Gianiorio F; Mij M; Simonato A; Viazzi F; Salvidio G; Garibotto G
Kidney Int; 2014 Dec; 86(6):1229-43. PubMed ID: 24786705
[TBL] [Abstract][Full Text] [Related]
16. Persistent Insulin Resistance in Podocytes Caused by Epigenetic Changes of SHP-1 in Diabetes.
Lizotte F; Denhez B; Guay A; Gévry N; Côté AM; Geraldes P
Diabetes; 2016 Dec; 65(12):3705-3717. PubMed ID: 27585521
[TBL] [Abstract][Full Text] [Related]
17. Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patients.
Steinke JM; Mauer M;
Pediatr Endocrinol Rev; 2008 Aug; 5 Suppl 4():958-63. PubMed ID: 18806710
[TBL] [Abstract][Full Text] [Related]
18. Protection of CTGF Antibody Against Diabetic Nephropathy in Mice Via Reducing Glomerular β-Catenin Expression and Podocyte Epithelial-Mesenchymal Transition.
Dai HY; Ma LN; Cao Y; Chen XL; Shi H; Fan YP; Yang B
J Cell Biochem; 2017 Nov; 118(11):3706-3712. PubMed ID: 28370212
[TBL] [Abstract][Full Text] [Related]
19. Implications of immunoglobulin G deposit in glomeruli in Chinese patients with diabetic nephropathy.
Zhang J; Zhang J; Zhang R; Wang Y; Liang Y; Yang Z; Wang T; Xu X; Liu F
J Diabetes; 2020 Jul; 12(7):521-531. PubMed ID: 32031751
[TBL] [Abstract][Full Text] [Related]
20. Podocytopathy in diabetes: a metabolic and endocrine disorder.
Diez-Sampedro A; Lenz O; Fornoni A
Am J Kidney Dis; 2011 Oct; 58(4):637-46. PubMed ID: 21719174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
